# Study to Assess the Bioavailability of Ticagrelor OD Tablet vs. IR Tablet

> **NCT02400333** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 100 (actual)

## Conditions studied

- Bioavailability
- Healthy Subjects

## Interventions

- **DRUG:** Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water
- **DRUG:** Ticagrelor OD tablet (90 mg single dose) administered without water
- **DRUG:** Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube
- **DRUG:** Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water

## Key facts

- **NCT ID:** NCT02400333
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2016-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02400333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02400333, "Study to Assess the Bioavailability of Ticagrelor OD Tablet vs. IR Tablet". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02400333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*